ESTRO PT 2018

H-N Phase II/III Randomized Trial (MDACC) Oropharyngeal Cancer - IMPT vs IMRT

IMPT (70 Gy(RBE)) Chemotherapy (locally advanced disease)

R A N D O M I Z A T I O N

Eligibility

Follow-up

No Surgery

1) Stage III-IV

oropharyngeal cancer

Recovery 10 wks

Treatment 33 days

PROs Q3 mo

Restaging

2) Squamous cell carcinoma

3) ECOG<2

Surgery

Follow-up

PROs

4) Target volume delineation

IMRT (70 Gy) Chemotherapy (locally advanced disease)

PROs Q3 mo

Primary endpoint: CTC-AE G3+ toxicity at 90 days – 2 years

Frank – PI Trial Activated – Sept 2013

Courtesy Steve Frank